secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2022-05-20T23:59:59+00:00
Accession:  0001193125-22-155640
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cortexyme completes Novosteo acquisition for ~6M shares; CLO departing
----------------------------------------------------------------------

- Completed merger with Novosteo; each Novosteo share converted to 0.0911 Cortexyme shares.
- Issued approximately 6 million shares (including options covering 507,108 shares) as consideration.
- Caryn McDowell, Chief Legal and Administrative Officer, to depart effective July 8, 2022.
- McDowell receives $339,000 cash severance, accelerated vesting, and extended option exercise period.
- Additional severance and benefits if change in control occurs within 3 months after departure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522155640/0001193125-22-155640-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522155640/d334868d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-155640

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer